138国国家基本药物清单抗生素与WHO AWaRe分类的一致性比较
该横断面研究比较了138个国家基本药物清单(NEML)中抗生素收录情况与2019年WHO模型清单及AWaRe分类数据库的一致性。结果显示多数国家覆盖评分较高,但部分国家缺乏储备类抗生素及优先感染的治疗覆盖,且覆盖评分因世界银行收入组别而异。
要点
- 138国NEML中必需抗生素中位数26种,41%国家未收录任何必需储备类抗生素。
- 95%国家覆盖评分≥60,但7%国家收录必需可及类抗生素不足12种。
- 急性新生儿脑膜炎和高风险发热性中性粒细胞减少症的治疗覆盖不足。
核心结论
- 各国NEML与AWaRe分类框架总体一致性较好,但储备类抗生素收录不足及部分优先感染治疗覆盖欠缺提示需调整清单以促进抗生素合理使用和遏制耐药。
研究设计与样本
- 横断面研究,从GEM数据库、WHO资源及各国网站获取138国2017年后更新的NEML,以2019年WHO模型清单中44种必需抗生素和AWaRe数据库中122种常用抗生素为参考标准进行评估。
主要发现
- 138国NEML中必需抗生素中位数为26种(IQR 21-32),102国(74%)收录至少22种(50%)。
- AWaRe抗生素中位数35种(IQR 29-46),可及类18种(16-21),慎用类16种(11-22),储备类1种(0-2)。
- 56国(41%)未收录任何必需储备类抗生素,131国(95%)覆盖评分≥60(相当于2019年WHO模型清单评分80的至少75%)。
- 9国(7%)收录必需可及类抗生素少于12/24种,7国(5%)优先感染覆盖评分低于60。
- 82国(59%)对急性新生儿脑膜炎未列出任何治疗,84国(61%)对高风险发热性中性粒细胞减少症仅列出一线、仅二线或无治疗。
关键数值与推荐
- 2019年WHO模型清单包含37种抗生素(考虑复方或等效药物后为44种独特抗生素),其中24种为可及类、15种为慎用类、5种为储备类。
- AWaRe分类数据库包含122种至少被一个国家收录的常用抗生素。
- 覆盖评分对每个优先感染按0-3分赋值,总分与2019年WHO模型清单评分80比较。
临床怎么用
- 感染科及抗菌药物管理团队可对照AWaRe分类评估本国NEML,优先补充储备类抗生素及急性新生儿脑膜炎、高风险发热性中性粒细胞减少症的治疗药物。
- 针对覆盖评分较低的国家,应优化NEML以纳入优先感染的一线和二线治疗,促进抗生素分层使用。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The WHO Model List of Essential Medicines classified antibiotics into Access, Watch, and Reserve (AWaRe) categories for the treatment of 31 priority bacterial infections as a tool to facilitate antibiotic stewardship and optimal use. We compared the listing of antibiotics on national essential medicines lists (NEMLs) to those in the 2019 WHO Model List and the AWaRe classification database to determine the degree to which NEMLs are in alignment with the AWaRe classification framework recommended by WHO. METHODS: In this cross-sectional study, we obtained up-to-date (data after 2017) NEMLs from our Global Essential Medicines (GEM) database, WHO online resources, and individual countries' websites. From the 2019 WHO Model List we extracted, as a reference standard, a list of 37 antibiotics (44 unique antibiotics after accounting for combination drugs or therapeutically equivalent drugs as specified by WHO) that were considered essential in treating 31 of the most common and severe clinical infectious syndromes (priority infections). From the WHO AWaRe Classification Database, which contains commonly used antibiotics globally, we extracted a list of 122 AWaRe antibiotics listed by at least one country in the GEM database. We then assessed individual countries' NEMLs for listing of the 44 essential and 122 commonly used antibiotics, overall and according to AWaRe classification group. We also evaluated and summarised the listing of both first-choice and second-choice treatments for the 31 priority infections. A total coverage score was calculated for each country by assigning a treatment score of 0-3 for each priority infection on the basis of whether first-choice and second-choice treatments, according to the 2019 WHO Model List, were included in the country's NEML. Coverage scores were then compared against the score of the 2019 WHO Model List and across World Bank income groups and WHO regions. FINDINGS: As of July 7, 2020, we had up-to-date NEMLs for 138 countries. Of the 44 unique essential antibiotics, 24 were Access, 15 were Watch, and five were Reserve. The median number of total essential antibiotics listed across the 138 NEMLs was 26 (IQR 21-32). 102 (74%) countries listed at least 22 (50%) of the 44 essential antibiotics. The median number of total AWaRe antibiotics listed by the 138 countries was 35 (IQR 29-46), of Access antibiotics was 18 (16-21), of Watch antibiotics was 16 (11-22), and of Reserve antibiotics was one (0-2). 56 (41%) countries did not list any essential Reserve antibiotics. 131 (95%) countries had coverage scores of at least 60, equivalent to at least 75% of the score of the 2019 WHO Model List, which was 80. Nine (7%) countries listed fewer than 12 of 24 essential Access antibiotics, and seven (5%) did not list sufficient first-choice and second-choice treatments for priority infections (ie, they had coverage scores lower than 60). Of the 31 priority infections, acute neonatal meningitis and high-risk febrile neutropenia did not have enough listed treatments, with 82 (59%) countries listing no treatment for acute neonatal meningitis and 84 (61%) countries listing only a first-choice treatment, only a second-choice treatment, or no treatment for high-risk febrile neutropenia. Coverage scores differed between countries on the basis of World Bank income groups (p=0·025). INTERPRETATION: Our findings highlight potential changes to the antibiotics included in NEMLs that would increase adherence to international guidance aimed at effectively treating infectious diseases while addressing antimicrobial resistance. FUNDING: Canadian Institutes of Health Research and Ontario Strategy for Patient Oriented Research Support Unit.
引用
- Adekoya I, Maraj D, Steiner L, et al. Comparison of antibiotics included in national essential medicines lists of 138 countries using the WHO Access, Watch, Reserve (AWaRe) classification: a cross-sectional study. Lancet Infect Dis. 2021. PMID: 34332706. doi:10.1016/S1473-3099(20)30854-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。